What ORF Genetics supplies
ORF Genetics is an Icelandic biotechnology company that produces recombinant growth factors and cytokines in barley grain. Its about page says production has run since 2001, when a team of plant biologists in Kopavogur set out to remove animal-derived contaminants from recombinant protein manufacturing. The company supplies researchers and manufacturers in cultivated meat, stem cell research and regenerative medicine.
It does not sell food protein. Its customers are the producers of cultivated meat and cultivated seafood, who need signalling proteins in the culture medium. The company ranks growth factors among the hardest parts of scaling cultivated meat because conventional supplies are built for research quantities, priced for laboratories and often derived from animal sources, which complicates a regulatory file.
Three product lines exist. ISOkine covers human and mouse growth factors for stem cell research, organoids and regenerative medicine. MESOkine is the line for cultivated meat and seafood. DERMOkine offers ingredients for skin and hair care. The company says all share one quality system and the same animal-free, endotoxin-free host, and that it is ISO 9001 certified.
The Orfeus barley platform
Orfeus is the barley-seed expression system. The technology page outlines the pipeline. A gene is codon-optimised and synthesised by a certified contract research firm, cloned into the proprietary GrainVec vector for seed-specific expression, and introduced into immature barley embryos by Agrobacterium. Tissue culture on selective media yields transgenic plantlets, and the best lines are chosen by measuring seed extract.
Only premium lines proceed to production. The company states that the process uses no bacteria, no animal inputs and no endotoxins, and it contrasts this with E. coli, a common host that sheds endotoxin during growth. It cites commonly accepted levels of 1 EU per microgram for commercial growth factors, against its own figure of below 0.01 EU per microgram.
The why-barley page lists further reasons: capacity grows by planting rather than building, barley is described as biologically non-permissive for mammalian viruses and prions, and seed protein bodies can store proteins that would harm a bacterial culture. It also admits a cost: adding a new protein takes longer than in a microbial host. Grain can be stockpiled and purified later.
MESOkine for cultivated meat
MESOkine is described as a dedicated line of species-specific growth factors, produced in barley, which the company calls a generally recognised as safe food crop. The cultivated meat page names bovine, porcine and avian proteins, with examples including FGF-2, IGF-1 LR3, PDGF-BB, VEGF, LIF, EGF and transferrin. Bioactivity is described as confirmed in independent commercial bioassays.
The pitch to producers has three points. Cost per dose is said to fall as volume rises, the same supply can serve bench and commercial scale, and an endotoxin-free plant host removes serum carryover, contaminating endogenous cytokines and prions. The page presents the line as a way to replace serum-containing media and animal-component growth factors.
The company also notes that barley seed proteins act as natural stabilisers that prolong shelf life. Buyers should still test lot-to-lot bioactivity in their own cell line, since a factor that performs in a commercial bioassay may behave differently in primary bovine or avian cells. Ordering is quote-based and requires no account.
Why growth factors matter in cultivated seafood and meat
Growth factors bind membrane receptors and trigger intracellular signalling that controls growth, proliferation and differentiation. Because small variations in purity or bioactivity carry through to a production batch, the company argues that a contaminated or inconsistent lot invalidates results and forces re-validation. That logic applies in food production too, where a failed bioreactor run costs far more than the reagent.
For cultivated seafood and meat developers, growth factors are a recurring cost line in the medium. The company positions plant-made factors as a route to lower cost at scale. Developers should compare dose requirements, stability in the medium and the effect of heat or freeze-thaw cycles on activity before committing to a supplier.
Another consideration is regulatory acceptability. Food authorities assess the whole process for cultivated products, including the inputs. A recombinant protein made in a transgenic crop raises questions about genetically modified origin, and the company states a quality path towards GMP. Producers should ask which documents the supplier can provide for a food-contact or food-ingredient dossier in the target market.
Quality, location and scale
The quality policy, revised in April 2026, says the company develops, produces and sells growth factors and cytokines based on its research into barley proteins, and commits to data-driven decisions and root cause analysis. The about page adds that it holds ISO 9001:2015 and is building towards GMP, a path that matters to customers who need documented supply chains.
Production takes place in a geothermal greenhouse on the Reykjanes Peninsula, powered by renewable energy, which the company says keeps production consistent year-round. The page gives a figure of 25 years of molecular farming, purity above 95% and three product lines. It reports 29 proteins established on one platform, so one crop serves several markets.
Commercial structure is simple: the site offers quote requests, with worldwide distribution and no account needed. The company separated from BioEffect in 2022 to become a standalone materials company. Buyers should ask about annual capacity for each protein, the harvest cycle that sets supply, and how the firm would cover a failed crop.
How a buyer would evaluate ORF Genetics
Start with the protein list. A cultivated meat team needs specific species and factors, so the first question is whether the bovine, porcine or avian version of each required protein is in the catalogue, at what purity and format. The company says a protein outside the portfolio takes longer to add.
Next, run a side-by-side bioassay. Cell growth, viability and differentiation markers should be compared against the current factor at equal dose, over several lots. Endotoxin figures, purity data and bioactivity certificates should come with each lot. If cost is the driver, calculate cost per litre of medium at production scale, not per milligram at research scale.
Finally, check the regulatory and supply file. Ask for documentation on the genetic modification status of the host, on removal of host proteins, and on the quality system covering each lot. Ask for supply terms that cover volume growth, price at scale and continuity during a poor harvest, since the plant is a living production system.